Japanese pharmaceutical firm Daiichi Sankyo's division, American Regent, has begun patient enrolment in the Phase III HEART-FID clinical trial of Injectafer (ferric carboxymaltose) for the treatment of heart failure with iron deficiency.

Injectafer is an intravenous (IV) form of iron being developed for the treatment of iron deficiency anaemia (IDA) in adults with an intolerance to oral iron or unsatisfactory response to oral iron or non-dialysis dependent chronic kidney disease.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The double-blind, multi-centre, prospective, randomised, placebo-controlled Phase III trial is expected to enrol more than 3,000 adult patients across North America.

The trial will evaluate the efficacy and safety of iron therapy using IV ferric carboxymaltose (FCM) as compared to placebo in heart failure patients with iron deficiency and a decreased ejection fraction.

"Heart failure in relation to iron deficiency is an important area of research for American Regent."

American Regent clinical research and development head Sumita Chowdhury said: "We are pleased to enrol our first patient in the HEART-FID trial, one of the largest studies looking at this specific condition, and we look forward to further recruitment.

"Heart failure in relation to iron deficiency is an important area of research for American Regent."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The trial's primary objectives are measuring one-year death rates, hospitalisation for worsening heart failure and the six-month change in the six-minute walk test (6MWT).

Eligible subjects will be divided by region and randomised in a 1:1 ratio to FCM or placebo for treatment, following an initial screening period of about 28 days.